Keyword: Amgen


HHS Says Nplate Order not Sign of Nuclear Threat

10.10.2022 -

The US Department of Health and Human Services (HHS) said last week it has budgeted $290 million to stock up on Amgen’s Nplate (romiplostim), a drug primarily used to...


Amgen Takes ChemoCentryx for $3.7 Billion

09.08.2022 -

Amgen is beefing up its inflammatory diseases portfolio with an agreement to buy US biopharma ChemoCentryx for roughly $3.7 billion. The deal gives Amgen access to...


Amgen Builds Biologics Facility in North Carolina

13.08.2021 -

US biotech Amgen is planning to spend $550 million on building a new biologics manufacturing plant in Holly Springs, Wake County in North Carolina. Construction is...


Amgen Boosts Antibody Portfolio with Teneobio Buy

02.08.2021 -

US biopharma Amgen has agreed to buy privately held clinical-stage biotech Teneobio in a deal worth up to $2.5 billion. The acquisition will expand Amgen’s antibody...


Amgen Boosts Oncology Portfolio with Five Prime Buy

10.03.2021 -

Amgen is to buy Five Prime Therapeutics, a clinical-stage biotech focused on developing immuno-oncology and targeted cancer therapies, for about $1.9 billion. The...


Amgen and China’s BeiGene in Oncology Partnership

04.11.2019 - US biotech Amgen has agreed to take a 20.5% stake in China’s BeiGene as the two companies enter into a strategic collaboration to develop cancer drugs. The move significantly...


Amgen Makes $13 billion Grab for Otezla

27.08.2019 - Contrary to recent speculation that Amgen was preparing to buy Alexion, the California-based US biotech has announced that it instead will acquire Celgene’s Otezla, the only oral...


Amgen Wins Enbrel Patent Case

19.08.2019 - The US District Court for the District of New Jersey has upheld two of Amgen’s patents for its top-selling drug Enbrel (etanercept) in a ruling against Sandoz, which has been...